T1	Participants 50 118	hyperglycemic patients with non-ST elevation acute coronary syndrome
T2	Participants 285 430	patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study
T3	Participants 1709 1776	patients with cardiovascular disease and poorly controlled diabetes
